Beta defensin-2 is reduced in central but not in distal airways of smoker COPD patients by Pace, E et al.
Beta Defensin-2 Is Reduced in Central but Not in Distal
Airways of Smoker COPD Patients
Elisabetta Pace1*., Maria Ferraro1., Marta Ida Minervini2, Patrizio Vitulo3, Loredana Pipitone3,
Giuseppina Chiappara1, Liboria Siena1, Angela Marina Montalbano1, Malcolm Johnson4, Mark
Gjomarkaj1
1 Institute of Biomedicine and Molecular Immunology, National Research Council, Palermo, Italy, 2Department of Pathology, University of Pittsburgh, Pittsburgh,
Pennsylvania, United States of America, 3Mediterranean Institute for Transplantation and for High Specialised Therapies, ISMETT, Palermo, Italy, 4GlaxoSmithKline
Research and Development Ltd., Uxbridge, Middlesex, United Kingdom
Abstract
Background: Altered pulmonary defenses in chronic obstructive pulmonary disease (COPD) may promote distal airways
bacterial colonization. The expression/activation of Toll Like receptors (TLR) and beta 2 defensin (HBD2) release by epithelial
cells crucially affect pulmonary defence mechanisms.
Methods: The epithelial expression of TLR4 and of HBD2 was assessed in surgical specimens from current smokers COPD (s-
COPD; n = 17), ex-smokers COPD (ex-s-COPD; n = 8), smokers without COPD (S; n = 12), and from non-smoker non-COPD
subjects (C; n = 13).
Results: In distal airways, s-COPD highly expressed TLR4 and HBD2. In central airways, S and s-COPD showed increased TLR4
expression. Lower HBD2 expression was observed in central airways of s-COPD when compared to S and to ex-s-COPD. s-
COPD had a reduced HBD2 gene expression as demonstrated by real-time PCR on micro-dissected bronchial epithelial cells.
Furthermore, HBD2 expression positively correlated with FEV1/FVC ratio and inversely correlated with the cigarette smoke
exposure. In a bronchial epithelial cell line (16 HBE) IL-1b significantly induced the HBD2 mRNA expression and cigarette
smoke extracts significantly counteracted this IL-1 mediated effect reducing both the activation of NFkB pathway and the
interaction between NFkB and HBD2 promoter.
Conclusions: This study provides new insights on the possible mechanisms involved in the alteration of innate immunity
mechanisms in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an increas-
ingly serious global health problem [1] and it is expected to be the
third most common cause of death in 2020 [2].
Distal airway bacterial colonization may occur in COPD
patients, who often have altered pulmonary defenses [3]. A key
component of the innate defences against infections is represented
by the toll like receptor (TLR) family [4]. Upon activation of TLR
by endogenous and exogenous ligands, the release of chemokines
including IL8 and IP-10 and of defensins may occur [5]. TLR2
and TLR4, predominantly expressed by monocytes/macrophages
and neutrophils [4], are also expressed by lung and bronchial
epithelial cells [6]. The airway epithelium is active in airway
defence mechanisms releasing cytoprotective mucus and defensins
[7] and plays an important role in coordinating local inflammation
and immune responses through the generation of cytokines and
chemokines [8].
The tobacco smoking habit interferes with the innate host
defense system by increasing mucus production, reducing
mucociliary clearance, reducing human beta 2 defensin
(HBD2) release [9], disrupting the epithelial barrier and
stimulating the migration of inflammatory cells into the damaged
tissue [10].
Although it is known that cigarette smoke exposure, a major
determinant of COPD, is able to alter the expression and the
activation of TLR4 in a bronchial epithelial cell line [11], it is
unknown whether this phenomenon occurs in vivo and whether it
is differently altered at different levels of the bronchial tree. In
COPD, the predominant pathology is present in peripheral
airways and lung parenchyma [12]. To what extent central
airways may mirror events occurring in distal lung is uncertain.
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The aim of the present study was to evaluate whether COPD is
associated to the alteration of the expression of TLR4 or to an
altered expression of human beta 2 defensin (HBD2) in central as
well as in distal airways.
Materials and Methods
Patient Population
Patients underwent surgery for lung cancer and were recruited
at ISMETT-Palermo, Italy. The study was approved by the
ISMETT Ethic Committee (#149311-29/05/2006) and was in
agreement with Helsinki Declaration. Written informed consent
was obtained from each patient. The following patient groups
were selected: 1) never smoking patients without COPD (C)
(n = 13); 2) smoking patients (.15 packs/year) without COPD (S)
(n = 12); 3) smoking patients (.15 packs/year) with COPD (s-
COPD) (n= 17); 4) ex smoker patients (.15 pack/year) who had
stopped to smoke by more than one year and with COPD (ex-s-
COPD) (n= 8). COPD patients were treated with bronchodilators
and were classified on the basis of preoperative lung function:
FEV1 less than 80% of reference, FEV1/FVC less than 70%, and
bronchodilatation effect less than 12%. The patients were not
under corticosteroid therapy (neither inhaled nor systemic) and not
under antibiotics and did not have exacerbations during the
month preceding the study. Subjects had negative skin tests for
common allergen extracts and had no past history of asthma or
allergic rhinitis.
Immunohistochemistry
Tissue specimens from tumor-free central bronchi and periph-
eral lung tissue were selected, fixed with 10% Neutral buffer
formalin and embedded in paraffin wax. Sequential sections (3 mm
thick) were placed on poly-L-lysine coated slides, deparaffinized in
xylene, rehydrated in a descending ethanol series and stained with
haematoxylin and eosin (HE).
Immunohistochemistry and image analysis were used to
determine TLR4, and HBD2 expression using rabbit polyclonal
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) in central
(internal perimeter .6 mm) and distal (internal perimeter , or
= 6 mm) airways [13]. LSAB2 Dako kit (Code Nu K0674) (Dako,
Glostrup, Denmark) and Fuchsin Substrate-Chromogen System
Dako [14] were used for the staining. Rabbit negative control
immunoglobulins (Dako) were used for negative controls. The
immunoreactivity was evaluated blindly by 2 independent
investigators using a Leica (Wetzlar, Germany) microscope6400
magnification. The length of the basement membrane was
evaluated using a Quantimet 500 MC software (Leica) for Image
Analysis. Results were expressed as the number of positive
epithelial cells/mm basement membrane as reported in a similar
COPD study [15].
Laser capture microdissection
Laser capture microdissection (LMD) was performed using the
Leica AS LMD (Leica Microsystems, Germany) [16] from three s-
COPD and three ex-s-COPD. Epithelial cells (recognized by
morphologic characteristics) were microdissected from the sample
into the cap of a microtube and then processed in the same tube.
Further details are provided in the online supplement.
Real time PCR
Real time PCR was performed as previously described [17].
Total cellular RNA was extracted from s-COPD and ex-s-COPD
micro-dissected tissues using RNeasy Microkit (Qiagen, Milan,
Italy) and reverse-transcribed to cDNA, using Superscript First-
Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA,
USA). Real-time quantitative PCR of HBD2 gene was carried out
on ABI PRISM 7900 HT Sequence Detection Systems (Applied
Biosystems, Foster City, CA, USA) using specific FAM-labeled
probe and primers (Applied Biosystems, TaqMan Assays on
Demand). GAPDH gene expression was used as endogenous
control for normalization. Relative quantification of mRNA was
carried out with comparative CT method.
Stimulation of bronchial epithelial cell lines
16-HBE, an immortalized normal bronchial epithelial cell line,
was used in this study [18].
16HBE were cultured with or without IL-1b (30 ng/ml) (R&D
System, Minneapolis, MN) and with or without 10% cigarette
smoke extracts (CSE) for 24 hrs as previously described [11]. At
the end of stimulation cell extracts were collected for assessing
HBD2 m-RNA expression by Real Time PCR and for assessing
HBD2 protein by flow cytometry, IkB protein expression by
western blot analysis and for ChiP analysis.
Flow cytometry
For flow cytometry, analyses were performed on a Becton
Dickinson FACSCalibur System using a rabbit polyclonal antibody
anti-HBD2 (Santa Cruz Biotechnology) followed by a fluorescein
isothio-cyanate (FITC) conjugated anti-rabbit IgG (Dako).
Analysis was done on 100,000 acquired events for each sample
using cellQuest acquisition and data analysis software (Becton
Dickinson (BD) Mountain View, CA). Negative controls were
performed using an isotype control antibody (BD PharMingen,
Mountain View, CA). For the detection of intracellular HBD2, 16-
HBE were cultured overnight with GolgiStop (2 mM final
concentration) (BD PharMingen). Cells, washed twice in PBS
with 1% FCS, were fixed with PBS containing 4% paraformal-
dehyde for 20 min at room temperature. After two washes in
permeabilization buffer (PBS containing 1% FCS, 0.3% saponin,
and 0.1% Na azide) for 15 min at 4uC, the cells were stained with
rabbit polyclonal antibody anti-HBD2 (Santa Cruz Biotechnology)
followed by a fluorescein isothio-cyanate (FITC) conjugated anti-
rabbit IgG (Dako)and then evaluated by flow-cytometry.
Western blot analysis
The expression of phosphorylated IkB alpha (p IkBa) was
evaluated by western blot analysis as previously described [11].
40 mg of total protein were loaded in the gel. All blots were first
probed using a rabbit polyclonal antibody anti-pIkBa (1:500) (Cell
Signaling Technology Inc) and a rabbit polyclonal antibody anti-
IkBa (1:1000) (Cell Signaling Technology Inc). Revelation was
performed with an enhanced chemioluminescence system (GE
Healthcare, Chalfont St. Giles, UK) followed by autoradiography.
Beta-actin (Sigma) was used as housekeeping protein to normalize
differences in protein loading.
ChiP Analysis
ChiP analysis was performed using the EZ-ChIP kit (Upstate-
Millipore Corporate- Billerica, MA) as previously described [19].
The 16-HBE were stimulated as above mentioned and the
crosslinked chromatin were sonicated to lengths spanning 200–
1000 bp. The samples were precleared with 60 ml of Protein A
Agarose and then incubated with a rabbit polyclonal antibody anti
human NFkB (Santa Cruz Biotechnology). Immunocomplexes were
precipitated using Protein A Agarose. After washing, DNA fragments
were isolated and purified with columns. PCR was performed using
primers spanning the promoter region of HBD2 gene using the
Innate Immunity Responses in COPD
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primers: sense 59-catcccccagtctcttcatct-39 and antisense 59-atgagac-
cagtgtccaggcta-39; sense 59-ggtgtgaatggaaggaactca-39 and antisense
59-ttcagctcctggggatgatac-39; sense 59-tggcaggttataggtcctgag-39 and
antisense 59-ataaaggtcctggtccctggt-39 [20].
Statistics
Age, clinical scores of the patients and Real time PCR data are
expressed as mean6 standard deviation. The Kruskal Wallis and
Mann Whitney U-test were used for comparisons between patient
groups. The Spearman test was used for correlations. Student’s
paired t test was used for in vitro experiments on 16HBE. P,0.05
was accepted as statistically significant.
Results
Demographic characteristics of the subjects
The demographic characteristics and the functional evaluations
of the studied groups are shown in Table 1. All recruited patient
groups were similar with regard to age.
The number of packs/year was similar between S and s-COPD
but it was significantly higher in s-COPD than in ex-s-COPD
(p,0.01).
TLR4 expression
Since smoking habit interferes with the innate host defense
system [10], we first assessed TLR4 expression in airway epithelial
cells of distal and of central airways. TLR4 expression was
increased in the epithelium of distal airways (figure 1 A and figure 2
A) in S, in s-COPD and in ex-s-COPD when compared to C. In
central airways TLR4 expression was increased in S and s-COPD
when compared to C and the TLR4 expression was significantly
higher in S than in s-COPD (figure 1 B and figure 2 B). TLR4
expression were detected in basal and in columnar epithelial cells.
HBD2 Expression
Since the activation of TLR4 leads to the release of defensins
[21], HBD2 expression was assessed. In the epithelium of distal
airways, HBD2 expression was increased in S, s-COPD and in ex-
s-COPD when compared to C (figure 3 A and figure 4 A). In the
epithelium of central airways, HBD2 expression was significantly
reduced in s-COPD when compared to S and to ex-s-COPD
(figure 3 B and figure 4 B).
Correlations
We assessed whether TLR4 and HBD2 expression, in distal and
in central airways, correlated with FEV1 and with FEV1/FVC
ratio or with cigarette smoke exposure (packs/year). No significant
correlation was found between these parameters and TLR4
expression (data not shown). A significant correlation was observed
between the HBD2 expression in central airways and FEV1/FVC
ratio (Figure 5 A) but not between HBD2 and FEV1 (data not
shown). Furthermore, HBD2 expression in central airways
inversely correlated with cigarette smoke exposure (packs/year)
(Figure 5 B).
HBD2 mRNA expression in microdissected bronchial
epithelium
To understand whether a reduced mRNA expression was
responsible of the different HBD2 expression between s-COPD
and ex-s-COPD in central airways, real time PCR was performed
on microdissected bronchial epithelium (figure 6 A) from the two
patient groups. Decreased HBD2 mRNA expression was observed
in s-COPD in comparison to ex-s-COPD (figure 6 B).
In vitro effects of cigarette smoke in bronchial epithelial
cells
To better explore the role of cigarette smoke exposure, HBD2
expression at both mRNA (figure 7 A) and protein level (figure 7 B)
was evaluated in IL1 beta and CSE stimulated bronchial epithelial
cells (16-HBE). CSE did not modify the constitutive expression of
HBD2. IL1 beta induced the HBD2 expression and CSE
significantly counteracted this IL-1 b mediated effect further
supporting the negative effect of cigarette smoke in the expression
of HBD2 by bronchial epithelial cells. The mechanisms underlin-
ing the inhibitory effects of CSE in HBD2 induction were further
explored. In bronchial epithelial cells, IL-1 beta increased the
expression of pIKBa leading to an increased activation of NFkB
pathway and CSE negatively interfered with this phenomenon
(figure 7 C).
Furthermore, we carried out ChIP assays with antibodies
specific to NFkB (figure 7 D) and the results of these experiments
showed that NFkB is detected on the promoter region of HBD2 in
bronchial epithelial cells after incubation with IL-1 b and this
phenomenon was reverted by the presence of CSE.
Discussion
COPD is a poorly understood and slowly evolving disease where
significant pathological anathomical changes are already present
at the diagnosis. Detailed inflammatory profiles of disease
phenotypes are now emerging in COPD.
Table 1. Demographic characteristics of the subjects.
Controls = 13 Smokers = 12 s-COPD=17 ex-s-COPD=8
Gender (M/F) 9/4 10/2 15/2 7/1
Age (years)
Means6SD
60613 6369 6468 7067
Packs/year - 59621 70631* 40624
FEV1 % of predicted
Means6SD
89616 77612 68615 7868
FEV1/FVC
% of predicted
Means Means6SD
8366 8069 6067 6564
*p,0.01 vs ex-COPD.
doi:10.1371/journal.pone.0033601.t001
Innate Immunity Responses in COPD
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This study demonstrates for the first time that an over-
expression of TLR4 is present in the epithelium of both central
and distal airways of s-COPD. HBD2 epithelial expression is
reduced in the epithelium of central airways while it is increased in
the epithelium of distal airways of s-COPD and this marker
correlates with airflow obstruction and with the packs/year of
smoking. The reduced expression of HBD2 in the epithelium of
central airways is due to the negative effect of CSE in NFkB
pathway activation.
In COPD, the predominant pathology is present in peripheral
airways and lung parenchyma [12]. To what extent central
airways may mirror events occurring in distal lung is uncertain.
Neutrophils are more numerous in the proximal bronchial tree
and macrophages are predominantly present in distal airways [22].
The inflammatory processes promote the structural and functional
changes associated with chronic bronchitis in the larger bronchi
[23] while in the smaller bronchi and bronchioles, they cause the
occlusion of the lumen by mucus, thickening of the walls, and
Figure 1. Expression of TLR4 in distal and in central airways. Immunohistochemistry for TLR4 in distal (A) and in central airways (B) from
surgical samples of Controls (n = 13), S (n = 12), s-COPD (n= 17) and ex-s-COPD (n= 8) subjects. Cells were stained with an anti-TLR4 antibody.
Negative control were performed using rabbit immunoglobulins negative control (see materials and methods for details). A) Individual counts for the
number of positive epithelial cells/mm basement membrane in distal airways. Horizontal bars represent median values. * p,0.05 values in figure
represent Mann-Whitney U test analyses. B) Individual counts for the number of positive epithelial cells/mm basement membrane in central airways.
Horizontal bars represent median values. * p,0.05 values in figure represent Mann-Whitney U test analyses.
doi:10.1371/journal.pone.0033601.g001
Figure 2. TLR4 immunostaining in distal and in central airways. A) Representative negative control and representative TLR4 immunostaining
(red stain) in distal airways of a Control, of a Smoker, of a s-COPD and of an ex-s-COPD. B) Representative negative control and representative TLR4
immunostaining (red stain) in central airways of a Control, of a Smoker, of a s-COPD and of an ex-s-COPD. For central airways a particular from a 4006
magnification was selected and showed.
doi:10.1371/journal.pone.0033601.g002
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narrowing of the lumen [12]. This study was designed to
understand whether innate immunity response mechanisms are
differently altered at different levels of the bronchial tree in
smokers and in COPD patients (current smokers and ex-smokers)
with stable disease.
Innate immunity relies on pattern recognition receptors that
recognize structures common to many microorganisms and
endogenous ligands such as heat shock proteins. A study from
Pons [24] showed that TLR-2 is up-regulated in peripheral blood
monocytes harvested from COPD patients, either when clinically
stable or when exacerbated. Droemann et al. [25] reported that
alveolar macrophages from stable COPD patients and smokers
express less TLR-2 than never smokers. We demonstrate here for
the first time that TLR4 expression is increased in central and
distal airway epithelium in both smokers and s-COPD. These
findings strongly suggest that the expression of TLRs may be
differently modified in different cell compartments (immunocom-
petent cells or airway epithelial cells) of the bronchial tree.
Furthermore, the increased expression of TLR4 in the epithelium
of central airways in smokers and in s-COPD is consistent with the
Figure 3. Expression of HBD2 in distal and in central airways. Immunohistochemistry for HBD2 in distal (A) and in central airways (B) from
surgical samples of Controls (n = 13), S (n = 12), s-COPD (n = 17) and ex-s-COPD (n= 8) subjects. Cells were stained with an anti-HBD2 antibody.
Negative control were performed using rabbit immunoglobulins negative control (see materials and methods for details). A) Individual counts for the
number of positive epithelial cells/mm basement membrane in distal airways. Horizontal bars represent median values. * p,0.05 values in figure
represent Mann-Whitney U test analyses. B) Individual counts for the number of positive epithelial cells/mm basement membrane in central airways.
Horizontal bars represent median values. * p,0.05 values in figure represent Mann-Whitney U test analyses.
doi:10.1371/journal.pone.0033601.g003
Figure 4. HBD2 immunostaining in distal and in central airways. A) Representative negative control and representative HBD2
immunostaining (red stain) in distal airways of a Control, a Smoker, a s-COPD and an ex-s-COPD. B) Representative negative control and
representative HBD2 immunostaining (red stain) in central airways of a Control, of a Smoker, of a s-COPD and of ex-s-COPD. For central airways a
particular from a 4006magnification was selected and showed.
doi:10.1371/journal.pone.0033601.g004
Innate Immunity Responses in COPD
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results of a previous in vitro study published by our group showing
that CSE increase the expression of TLR4 in a bronchial epithelial
cell line [11].
TLRs establish the inflammatory setting in response to
infections or tissue damage and provides a low-grade activation
of the innate immune system for day-to-day lung structure stability
[25]. High grade activation of TLR signalling leading to increased
production of cytokines and reactive oxidant contributes to
experimental emphysema [26].
CSE in mice induce airway neutrophilia via activation of
TLR4 signalling [27] and in bronchial epithelial cells, in vitro,
orientate the activation of TLR4 toward an increased IL-8
release and a reduced IP-10 release leading to an increased
neutrophil chemotaxis and to a reduced lymphocyte chemotaxis
thus altering the balance between innate and adaptative
responses [11]. This unbalance may amplify lung inflammation
since lung inflammation can be excessive when the adaptive
pulmonary immune responses are inappropriate [28]. TLR4
activation by external agents is mainly due to gram negative
bacteria and is also finalized to the release of antimicrobial
peptides including HBD2, a molecule with a potent effect against
gram negative bacteria [20]. Respiratory epithelial cells require
TLR4 for the induction of HBD2 by LPS [29]. HBD2, mainly
present in structural epithelial cells, exerts specific chemotactic
activity for neutrophils [30] and may amplify TLR responses
acting as an endogenous TLR ligand [31]. We show here that
HBD2 is reduced in central airways of s-COPD patients when
compared to smoker subjects and COPD who stopped to smoke
and correlates with the degree of airway obstruction assessed by
the reduction in FEV1/FVC ratio that, as previously reported
[32], is a good spirometric parameter to represent airflow
limitation. Moreover, HBD2 expression in central airways
inversely correlates with pack/years of smoking, strongly
suggesting that cigarette smoke exposure crucially negatively
affects the expression of HBD2 in COPD patients. In this regard,
it has been recently demonstrated that cigarette smoke extracts
reduce the expression of HBD2 in primary bronchial epithelial
cells from smokers and from COPD patients [9].Our in vitro
experiments showing that the exposure of CSE in bronchial
epithelial cells blocks the induction of HBD2 mRNA generated
by exposure to IL-1 b, a cytokine with a crucial role in the
inflammation of COPD, confirm and extend these observation
providing some explanation on the mechanisms that contribute to
this phenomenon. Cigarette smoke interferes with the innate host
Figure 5. Correlations between the expression of HBD2 in central airways and functional parameters. The expression of HBD2 in central
airways of Controls (n = 13), S (n = 12), s-COPD (n= 17) and ex-s-COPD (n= 8) was correlated with FEV1/FVC ratio (A) and packs/year (B) by Spearman
Correlation test.
doi:10.1371/journal.pone.0033601.g005
Figure 6. Expression of HBD2 m-RNA in central airways. HBD2 m-RNA expression was assessed by Real time PCR in microdissected bronchial
epithelium from s-COPD (n= 3) and from ex-s-COPD (n= 3) (see materials and methods for details). A) Representative images showing the bronchial
epithelium before (on the left) and after (on the right) laser microdissection (LMD). B) Expression of HBD2 m-RNA in microdissected bronchial
epithelium. GAPDH gene expression was used as endogenous control for normalization. Relative quantitation of mRNA was carried out with
comparative CT method. (mean6SD). * p,0.05.
doi:10.1371/journal.pone.0033601.g006
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defence system by increasing mucus production, reducing
mucociliary clearance, disrupting the epithelial barrier and
stimulating the migration of inflammatory and immune cells
[28]. In addition, the exposure of airway epithelium to smoke
blocks the LPS-induced activation of NFkB pathway [11] [33], a
signal pathway with a crucial role in the HBD2 synthesis.
Accordingly, it has been previously described that the exposure of
airway epithelium to smoke inhibits the HBD2 induction by
bacteria [34]. To further support these data, in the present study,
we demonstrate that CSE inhibits IL-1 b induced NFkB pathway
activation and in turn negatively interferes with the interaction
between NFkB and the promoter region of HBD2. Subjects with
reduced HBD2 gene copies are predisposed to Crohn’s disease
[35] and here, a reduced HBD2 expression in the epithelium of
central airways is present in s-COPD further supporting the
concept that the de-regulation of the HBD2 expression in a
specific compartment of the bronchial tree may contribute to the
disease development. Additional mechanisms may account for
the reduced HBD2 expression in central airways of current
smoker COPD. HBD2 synthesis may be promoted by leptin [36]
and in epithelial cells of bronchial biopsies, the expression of
leptin and its receptors is reduced in mild-to-severe COPD
patients [37].
Since not all smokers develop COPD [38], the reduced
expression of HBD2 in central airways might identify smokers
susceptible to develop COPD. Further studies are needed to
validate this hypothesis. Moreover, decreased HBD2 together with
an increased TLR4 expression in central airway epithelium may
suggest an impairment in the activation of innate responses at this
level that in turn may favour the microbial invasion to distal airways
and to the parenchyma. Physiologically, the distal airways are sterile
while the airways of COPD patients are chronically colonized by
potential respiratory pathogens [39]. Chronic bacterial colonization
together to an oxidant/antioxidant unbalance can stimulate the
host immune system and cause a chronic airway inflammation [40]
that in turn may promote the tissue damage observed in distal
airways and lung parenchyma of COPD patients. Bronchiolar
inflammation correlates with functional impairment and temporally
precedes emphysema [22]. Our findings that in distal airways of s-
COPD both HBD2 and TLR4 epithelial expression are increased
support the concept that an increased activation of innate immunity
responses may occur at this level. In the distal airways of smokers
with COPD and acute respiratory failure high levels of HBD2
increase neutrophil survival [40] thus contributing to amplify the
inflammatory responses which, in turn, promote the occlusion of the
lumen by mucus, thickening of the walls, and narrowing. In
addition, ex-s-COPD have an increased epithelial HBD2 expression
in central airways further supporting the concept that smoking
cessation may alter the inflammatory profile of the airway epithelial
cells. Ex-smokers with COPD have significantly less epithelial
squamous cell metaplasia, proliferating cell numbers, and show a
trend towards reduced goblet cell area than current smokers with
COPD [41].
In conclusion, this study demonstrates that although an over-
expression of TLR4 is present in central and in distal airways of s-
COPD and of S, HBD2 is reduced in central airways but not in
distal airways of s-COPD and correlates with the degree of airflow
obstruction and with smoking history.
Figure 7. Effects of CSE in bronchial epithelial cells (16-HBE). 16-HBE cells were cultured in the presence and in the absence of IL-1 b and of
CSE (10%) (n = 3) (see materials and methods for details). A) Expression of HBD2 m-RNA in 16-HBE by real time PCR. GAPDH gene expression was used
as endogenous control for normalization. Relative quantitation of mRNA was carried out with comparative CT method. (mean6SD). * p,0.05 versus
baseline. ** p,0.05 versus IL-1 beta. B) Representative experiment (one out of three experiments) showing the expression of HBD2 protein in 16-HBE
by flow cytometry. The expression of HBD2 is expressed as percentage of HBD2 positive cells. C) Evaluation of p-IkBa or t-IkBa by western blot
analysis. Membranes were then stripped and incubated with goat polyclonal anti–ß-actin. Representative western blot analysis (one out of three
experiments). Lane1=baseline; lane 2 =CSE 10%;lane 3 = IL1 beta; lane 4 =CSE+IL1 beta. D) ChiP assay using anti-NFkB antibody and PCR using
primers (forward 59-GGTGTGAATGGAAGGAACTCA-39 reverse 59-TTCAGCTCCTGGGGATGATAC-39) spanning the promoter region of HBD2 gene were
performed (see Materials and Methods for details) One out of two experiments is shown. Lane 1 =DNA marker; Lane 2 =baseline; lane 3=CSE 10%;
lane 4 = IL1 b; lane 5 =CSE+IL1 b.
doi:10.1371/journal.pone.0033601.g007
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